Table 2.
Variables | Size of tumor | P-Value | |
---|---|---|---|
5–9.9 cm (n = 253) | ≥ 10 cm (n = 38) | ||
Age (y) | 49.20 ± 11.16 | 48.75 ± 10.45 | 0.943 |
Gender | 0.570 | ||
Male | 85 (33.60%) | 11 (28.95%) | |
Female | 168 (66.40%) | 27 (71.05%) | |
Comorbidities, N (%) | |||
Gallbladder polyps | 12 (4.74%) | 3 (7.89%) | 0.670 |
Hypertension | 44 (17.39%) | 9 (23.68%) | 0.349 |
Type 2 diabetes mellitus | 10 (3.95%) | 2 (5.26%) | 1.000 |
Hepatitis B/C | 10 (3.95%) | 3 (7.89%) | 0.499 |
Hepatic cysts | 11 (4.35%) | 3 (7.89%) | 0.577 |
Child-Pugh grading, N (%) | 1.000 | ||
Glass A | 246 (97.23%) | 37 (97.37%) | |
Glass B | 7 (2.77%) | 1 (2.63%) | |
No. of tumor | 0.868 | ||
Single lesion | 241 (95.26%) | 37 (97.37%) | |
Two lesion | 12 (4.74%) | 1 (2.63%) | |
Distribution of lesion, N (%) | 0.074 | ||
Right lobe | 134 (52.96%) | 25 (65.79%) | |
Left lobe | 78 (30.83%) | 12 (31.58%) | |
Both | 41 (16.21%) | 1 (2.63%) | |
Reason for RFA, N (%) | 0.003 | ||
Abdominal pain | 73 (28.85%) | 21 (55.26%) | |
Enlargement of hemangioma | 101 (39.92%) | 7 (18.42%) | |
Abdominal pain and enlargement hemangioma | 79 (31.23%) | 10 (26.32%) | |
Laboratory findings | |||
Hb (g/L) | 135.13 ± 15.87 | 130.55 ± 14.81 | 0.097 |
ALT (U/L) | 21.42 ± 20.91 | 17.72 ± 8.10 | 0.289 |
AST (U/L) | 23.78 ± 40.15 | 18.23 ± 4.14 | 0.659 |
TBil (μmol/L) | 12.53 ± 5.20 | 13.90 ± 6.91 | 0.247 |
BUN (mmol/L) | 4.95 ± 1.47 | 4.84 ± 1.23 | 0.614 |
Creatinine (μmol/L) | 70.57 ± 36.30 | 65.33 ± 12.51 | 0.484 |
PT (s) | 12.18 ± 1.33 | 12.87 ± 4.68 | 0.376 |
APTT (s) | 31.38 ± 4.32 | 32.85 ± 6.65 | 0.074 |
Continuous variables are expressed by median ± standard deviation.
Hb, hemoglobin; TBil, total bilirubin; ALT, alanine aminotransferase; AST, aspartate transaminase; BUN, blood urea nitrogen.
PT, prothrombin time; APTT, activated partial thromboplastin time.
For the patients with multiple hepatic hemangiomas, the hepatic hemangiomas not managed were not included statistical range.